Novartis is expanding its presence in prostate cancer with the acquisition of the small molecule drug ARV-766 from Arvinas for $150 million upfront, with the potential for up to $1 billion more based on milestones. ARV-766 targets disease-causing proteins for disposal by the cell’s built-in system. The drug has shown promise in targeting androgen receptor tumors with mutations or amplifications. Novartis will now be responsible for the development and commercialization of ARV-766. This deal highlights the potential of targeted protein degradation therapies in treating various cancers, and it further validates Arvinas’s innovative protein degrader platform.
Source link
Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer
